Novo Nordisk engages in research, manufacturing, and distribution of pharmaceutical products globally. It operates two segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes segment provides products for diabetes, obesity, and cardiovascular therapy areas. The Rare Disease segment offers products for rare blood disorders, endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, injection needles, and smart solutions for diabetes treatment.
| Indicator | Value |
|---|---|
| PER | 19.0 |
| EV/EBITDA | 11.7 |
| Price/Free Cash Flow' | 16.4 |
| ROIC | 24.0% |
| Net Debt/EBITDA | 0.9 |